Animesh D Pardanani

List of Publications by Year
in descending order

354 papers	16,090 citations	20759 60 h-index	18075 120 g-index
354 all docs	354 docs citations	354 times ranked	8725 citing authors

#	Article	IF	Citations
1	Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis. New England Journal of Medicine, 2010, 363, 1117-1127.	13.9	1,046
2	MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood, 2006, 108, 3472-3476.	0.6	963
3	DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status. Journal of Clinical Oncology, 2011, 29, 392-397.	0.8	854
4	Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet. Journal of Clinical Oncology, 2011, 29, 761-770.	0.8	724
5	Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood, 2014, 124, 2507-2513.	0.6	575
6	Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study. Journal of Clinical Oncology, 2011, 29, 1356-1363.	0.8	485
7	Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood, 2009, 113, 5727-5736.	0.6	484
8	MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis. Journal of Clinical Oncology, 2018, 36, 310-318.	0.8	373
9	Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis. Journal of Clinical Oncology, 2011, 29, 789-796.	0.8	369
10	CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood, 2003, 102, 3093-3096.	0.6	368
11	Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis. JAMA Oncology, 2015, 1, 643.	3.4	362
12	FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood, 2004, 104, 3038-3045.	0.6	297
13	Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood, 2013, 122, 1395-1398.	0.6	286
14	Myeloproliferative Neoplasms. JAMA Oncology, 2015, 1, 97.	3.4	266
15	MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis. Journal of Clinical Oncology, 2018, 36, 1769-1770.	0.8	249
16	Targeted deep sequencing in polycythemia vera and essential thrombocythemia. Blood Advances, 2016, 1, 21-30.	2.5	243
17	GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. Leukemia, 2018, 32, 1631-1642.	3.3	213
18	Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood, 2003, 101, 3391-3397.	0.6	206

#	Article	IF	Citations
19	The Myelofibrosis Symptom Assessment Form (MFSAF): An evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leukemia Research, 2009, 33, 1199-1203.	0.4	203
20	One Thousand Patients With Primary Myelofibrosis: The Mayo Clinic Experience. Mayo Clinic Proceedings, 2012, 87, 25-33.	1.4	181
21	Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients. American Journal of Hematology, 2014, 89, E121-4.	2.0	176
22	Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferonâ€alpha, hydroxyurea, imatinib mesylate or 2â€chlorodeoxyadenosine. American Journal of Hematology, 2009, 84, 790-794.	2.0	166
23	Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. Blood, 2009, 114, 3769-3772.	0.6	157
24	Phase II Study of Dasatinib in Philadelphia Chromosomeâ€“Negative Acute and Chronic Myeloid Diseases, Including Systemic Mastocytosis. Clinical Cancer Research, 2008, 14, 3906-3915.	3.2	151
25	Clinical correlates ofJAK2V617F allele burden in essential thrombocythemia. Cancer, 2007, 109, 2279-2284.	2.0	149
26	Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation. British Journal of Haematology, 2007, 138, 354-358.	1.2	139
27	LNKMutations inJAK2Mutationâ€“Negative Erythrocytosis. New England Journal of Medicine, 2010, 363, 1189-1190.	13.9	138
28	Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders. Blood, 2008, 111, 2785-2789.	0.6	135
29	The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants. Blood, 2014, 124, 2465-2466.	0.6	135
30	Mutationâ€enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera. British Journal of Haematology, 2020, 189, 291-302.	1.2	134
31	Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management. American Journal of Hematology, 2018, 94, 363-377.	2.0	133
32	Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition. Nature Medicine, 2015, 21, 1473-1480.	15.2	128
33	International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. Blood, 2013, 121, 2393-2401.	0.6	122
34	In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. Blood, 2014, 124, 3021-3023.	0.6	112
35	Essential Thrombocythemia. New England Journal of Medicine, 2019, 381, 2135-2144.	13.9	106
36	Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management. American Journal of Hematology, 2021, 96, 508-525.	2.0	104

#	Article	IF	Citations
37	3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. Mayo Clinic Proceedings, 2019, 94, 599-610.	1.4	103
38	Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients. Leukemia, 2018, 32, 1189-1199.	3.3	102
39	Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts. Leukemia, 2018, 32, 1200-1210.	3.3	101
40	Driver mutations and prognosis in primary myelofibrosis: Mayoâ€Careggi MPN alliance study of 1,095 patients. American Journal of Hematology, 2018, 93, 348-355.	2.0	94
41	Targeted next-generation sequencing in blast phase myeloproliferative neoplasms. Blood Advances, 2018, 2, 370-380.	2.5	90
42	Systemic mastocytosis in adults: 2017 update on diagnosis, risk stratification and management. American Journal of Hematology, 2016, 91, 1146-1159.	2.0	88
43	Systemic mastocytosis in adults: a review on prognosis and treatment based on 342 Mayo Clinic patients and current literature. Current Opinion in Hematology, 2010, 17, 125-132.	1.2	84
44	Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients. American Journal of Hematology, 2020, 95, 1511-1521.	2.0	83
45	How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to) Tj ETQq1 1 0.784314 rgBT /Overlock	0.6	80
46	Eosinophils are derived from the neoplastic clone in patients with systemic mastocytosis and eosinophilia. Leukemia Research, 2003, 27, 883-885.	0.4	79
47	WHO subvariants of indolent mastocytosis: clinical details and prognostic evaluation in 159 consecutive adults. Blood, 2010, 115, 150-151.	0.6	78
48	ASXL1 mutations are frequent and prognostically detrimental in CSF3Râ€mutated chronic neutrophilic leukemia. American Journal of Hematology, 2015, 90, 653-656.	2.0	76
49	2-Chlorodeoxyadenosine Therapy for Disseminated Langerhans Cell Histiocytosis. Mayo Clinic Proceedings, 2003, 78, 301-306.	1.4	75
50	U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions. Leukemia, 2018, 32, 2274-2278.	3.3	75
51	Clinical, genetic, and therapeutic insights into systemic mast cell disease. Current Opinion in Hematology, 2004, 11, 58-64.	1.2	73
52	Systemic mastocytosis in adults: 2015 update on diagnosis, risk stratification, and management. American Journal of Hematology, 2015, 90, 250-262.	2.0	73
53	Targeted nextâ€generation sequencing in myelodysplastic syndromes and prognostic interaction between mutations and IPSSâ€R. American Journal of Hematology, 2017, 92, 1311-1317.	2.0	73
54	Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management. American Journal of Hematology, 2013, 88, 612-624.	2.0	71

#	Article	IF	Citations
55	Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosis. Blood, 2003, 101, 827-830.	0.6	69
56	Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models. Blood Advances, 2018, 2, 2964-2972.	2.5	68
57	Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)â€"a study of 1084 patients. Leukemia, 2020, 34, 1407-1421.	3.3	68
58	ExtendingJak2V617F andMplW515 Mutation Analysis to Single Hematopoietic Colonies and B and T Lymphocytes. Stem Cells, 2007, 25, 2358-2362.	1.4	65
59	Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically annotated patients. Blood, 2011, 118, 4595-4598.	0.6	64
60	Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis. American Journal of Hematology, 2013, 88, 312-316.	2.0	64
61	Nextâ€generation sequencing in systemic mastocytosis: Derivation of a mutationâ€augmented clinical prognostic model for survival. American Journal of Hematology, 2016, 91, 888-893.	2.0	60
62	Systemic mastocytosis in adults: 2012 Update on diagnosis, risk stratification, and management. American Journal of Hematology, 2012, 87, 401-411.	2.0	57
63	Momelotinib treatmentâ€emergent neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosis. British Journal of Haematology, 2015, 169, 77-80.	1.2	56
64	Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger. American Journal of Hematology, 2018, 93, 1474-1484.	2.0	56
65	CALR mutations and a new diagnostic algorithm for MPN. Nature Reviews Clinical Oncology, 2014, 11, 125-126.	12.5	53
66	Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model. Blood Cancer Journal, 2019, 9, 12.	2.8	52
67	Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients. American Journal of Hematology, 2019, 94, 767-779.	2.0	51
68	Evaluating the serial use of the myelofibrosis symptom assessment form for measuring symptomatic improvement. Cancer, 2011, 117, 4869-4877.	2.0	50
69	Mutations and prognosis in myelodysplastic syndromes: karyotypeâ€adjusted analysis of targeted sequencing in 300 consecutive cases and development of a genetic risk model. American Journal of Hematology, 2018, 93, 691-697.	2.0	50
70	Momelotinib therapy for myelofibrosis: a 7-year follow-up. Blood Cancer Journal, 2018, 8, 29.	2.8	49
71	Systemic Mastocytosis: A Concise Clinical and Laboratory Review. Archives of Pathology and Laboratory Medicine, 2007, 131, 784-791.	1.2	49
72	JAK2V617F Mutation Screening as Part of the Hypercoagulable Work-up in the Absence of Splanchnic Venous Thrombosis or Overt Myeloproliferative Neoplasm: Assessment of Value in a Series of 664 Consecutive Patients. Mayo Clinic Proceedings, 2008, 83, 457-459.	1.4	47

#	Article	IF	Citations
73	Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia. American Journal of Hematology, 2016, 91, 503-506.	2.0	47
74	Venetoclax with azacitidine or decitabine in blastâ€phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases. American Journal of Hematology, 2021, 96, 781-789.	2.0	46
75	The effect of arterial hypertension on thrombosis in lowâ€risk polycythemia vera. American Journal of Hematology, 2017, 92, E5-E6.	2.0	45
76	FIP1L1-PDGFRA and c-kit D816V mutation-based clonality studies in systemic mast cell disease associated with eosinophilia. Haematologica, 2004, 89, 871-3.	1.7	45
77	Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: analysis based on 1109 consecutive patients. Leukemia, 2018, 32, 1254-1258.	3.3	42
78	Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 1500-1537.	2.3	41
79	Flt-3 and c-kit mutation studies in a spectrum of chronic myeloid disorders including systemic mast cell disease. Leukemia Research, 2003, 27, 739-742.	0.4	40
80	Monocytosis in polycythemia vera: Clinical and molecular correlates. American Journal of Hematology, 2017, 92, 640-645.	2.0	40
81	How I treat myelofibrosis after failure of JAK inhibitors. Blood, 2018, 132, 492-500.	0.6	40
82	Systemic Mast Cell Disease Without Associated Hematologic Disorder: A Combined Retrospective and Prospective Study. Mayo Clinic Proceedings, 2002, 77, 1169-1175.	1.4	38
83	Targeting myeloproliferative neoplasms with JAK inhibitors. Current Opinion in Hematology, 2011, 18, 105-110.	1.2	38
84	Genotypeâ€“phenotype correlation of hereditary erythrocytosis mutations, a single center experience. American Journal of Hematology, 2018, 93, 1029-1041.	2.0	38
85	Updated results of the placeboâ€controlled, phase III JAKARTA trial of fedratinib in patients with intermediateâ€2 or highâ€risk myelofibrosis. British Journal of Haematology, 2021, 195, 244-248.	1.2	37
86	JAK2 unmutated erythrocytosis: current diagnostic approach and therapeutic views. Leukemia, 2021, 35, 2166-2181.	3.3	35
87	Monocytosis is a powerful and independent predictor of inferior survival in primary myelofibrosis. British Journal of Haematology, 2018, 183, 835-838.	1.2	32
88	Systemic mastocytosis in adults: 2011 update on diagnosis, risk stratification, and management. American Journal of Hematology, 2011, 86, 362-371.	2.0	31
89	Prefibrotic versus overtly fibrotic primary myelofibrosis: clinical, cytogenetic, molecular and prognostic comparisons. British Journal of Haematology, 2018, 182, 594-597.	1.2	31
90	Splanchnic vein thrombosis in patients with myeloproliferative neoplasms: The <scp>M</scp>ayo clinic experience with 84 consecutive cases. American Journal of Hematology, 2018, 93, E61-E64.	2.0	31

#	Article	IF	Citations
91	Myelofibrosis Treatment Algorithm 2018. Blood Cancer Journal, 2018, 8, 72.	2.8	31
92	Update On The Long-Term Efficacy and Safety Of Momelotinib, a JAK1 and JAK2 Inhibitor, For The Treatment Of Myelofibrosis. Blood, 2013, 122, 108-108.	0.6	31
93	Discordant distribution of JAK2V617F mutation in siblings with familial myeloproliferative disorders. Blood, 2006, 107, 4572-4573.	0.6	30
94	Neurologic symptoms and diagnosis in adults with mast cell disease. Clinical Neurology and Neurosurgery, 2011, 113, 570-574.	0.6	30
95	Infrequent occurrence of MPL exon 10 mutations in polycythemia vera and postâ€polycythemia vera myelofibrosis. American Journal of Hematology, 2011, 86, 701-702.	2.0	29
96	Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation. Blood Cancer Journal, 2021, 11, 49.	2.8	28
97	INCB018424, an Oral, Selective JAK2 Inhibitor, Shows Significant Clinical Activity in a Phase I/II Study in Patients with Primary Myelofibrosis (PMF) and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF).. Blood, 2007, 110, 558-558.	0.6	28
98	Circulating levels of MCPâ€1, sILâ€2R, ILâ€15, and ILâ€8 predict anemia response to pomalidomide therapy in myelofibrosis. American Journal of Hematology, 2011, 86, 343-345.	2.0	27
99	Gender and survival in essential thrombocythemia: A twoâ€center study of 1,494 patients. American Journal of Hematology, 2017, 92, 1193-1197.	2.0	27
100	JAK2 exon 12 mutated polycythemia vera: Mayoâ€Careggi MPN Alliance study of 33 consecutive cases and comparison with JAK2V617F mutated disease. American Journal of Hematology, 2018, 93, E93-E96.	2.0	27
101	Mast cell activation syndrome: Importance of consensus criteria and call for research. Journal of Allergy and Clinical Immunology, 2018, 142, 1008-1010.	1.5	27
102	CSF3R-mutated chronic neutrophilic leukemia: long-term outcome in 19 consecutive patients and risk model for survival. Blood Cancer Journal, 2018, 8, 21.	2.8	26
103	<scp>WHO</scp> defined chronic eosinophilic leukemia, not otherwise specified (<scp>CEL</scp>,) Tj ETQq1 1 0.784314 rgBT /Over 95, E172-E174.	2.0	26
104	Mutations and thrombosis in essential thrombocythemia. Blood Cancer Journal, 2021, 11, 77.	2.8	26
105	Primer on Medical Genomics Part IV: Expression Proteomics. Mayo Clinic Proceedings, 2002, 77, 1185-1196.	1.4	25
106	Chronic basophilic leukemia: a distinct clinico-pathologic entity?. European Journal of Haematology, 2003, 71, 18-22.	1.1	25
107	Vitamin D insufficiency in myeloproliferative neoplasms and myelodysplastic syndromes: Clinical correlates and prognostic studies. American Journal of Hematology, 2011, 86, 1013-1016.	2.0	25
108	ASXL1 and CBL mutations are independently predictive of inferior survival in advanced systemic mastocytosis. British Journal of Haematology, 2016, 175, 534-536.	1.2	25

#	Article	IF	Citations
109	A comparison of clinical and molecular characteristics of patients with systemic mastocytosis with chronic myelomonocytic leukemia to CMML alone. Leukemia, 2018, 32, 1850-1856.	3.3	25
110	Mutations and karyotype predict treatment response in myelodysplastic syndromes. American Journal of Hematology, 2018, 93, 1420-1426.	2.0	25
111	Spectrum of abnormalities and clonal transformation in germline RUNX1 familial platelet disorder and a genomic comparative analysis with somatic RUNX1 mutations in MDS/MPN overlap neoplasms. Leukemia, 2020, 34, 2519-2524.	3.3	25
112	Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders. Leukemia Research, 2004, 28, 47-52.	0.4	24
113	Biallelic inactivation of the retinoblastoma gene results in transformation of chronic myelomonocytic leukemia to a blastic plasmacytoid dendritic cell neoplasm: shared clonal origins of two aggressive neoplasms. Blood Cancer Journal, 2018, 8, 82.	2.8	24
114	Cytogenetic abnormalities in systemic mastocytosis: WHO subcategoryâ€specific incidence and prognostic impact among 348 informative cases. American Journal of Hematology, 2018, 93, 1461-1466.	2.0	24
115	Validation of the WHO-defined 20% circulating blasts threshold for diagnosis of leukemic transformation in primary myelofibrosis. Blood Cancer Journal, 2018, 8, 57.	2.8	23
116	Cytogenetic findings in <scp>WHO</scp>â€defined polycythaemia vera and their prognostic relevance. British Journal of Haematology, 2018, 182, 437-440.	1.2	22
117	A Phase I/II Study of CYT387, An Oral JAK-1/2 Inhibitor, In Myelofibrosis: Significant Response Rates In Anemia, Splenomegaly, and Constitutional Symptoms. Blood, 2010, 116, 460-460.	0.6	22
118	Differential expression of CD2 on neoplastic mast cells in patients with systemic mast cell disease with and without an associated clonal haematological disorder. British Journal of Haematology, 2003, 120, 691-694.	1.2	21
119	Risk factors and a prognostic model for postsplenectomy survival in myelofibrosis. American Journal of Hematology, 2017, 92, 1187-1192.	2.0	21
120	Singleâ€agent cladribine as an effective frontâ€line therapy for adults with Langerhans cell histiocytosis. American Journal of Hematology, 2021, 96, E146-E150.	2.0	21
121	Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1248-1269.	2.3	21
122	Next generation sequencing of myeloid neoplasms with eosinophilia harboring the FIP1L1â€PDGFRA mutation. American Journal of Hematology, 2016, 91, E10-1.	2.0	20
123	Targeted next generation sequencing of <scp>PDGFRB</scp> rearranged myeloid neoplasms with monocytosis. American Journal of Hematology, 2016, 91, E12-4.	2.0	20
124	Mayo Alliance Prognostic Model for Myelodysplastic Syndromes: Integration of Genetic and Clinical Information. Mayo Clinic Proceedings, 2018, 93, 1363-1374.	1.4	20
125	Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients. American Journal of Hematology, 2021, 96, 1472-1480.	2.0	20
126	Myelofibrosis: Genetic Characteristics and the Emerging Therapeutic Landscape. Cancer Research, 2022, 82, 749-763.	0.4	20

#	Article	IF	Citations
127	Systemic Mastocytosis. Hematology/Oncology Clinics of North America, 2012, 26, 1117-1128.	0.9	19
128	Prognostic interaction between bone marrow morphology and SF3B1 and ASXL1 mutations in myelodysplastic syndromes with ring sideroblasts. Blood Cancer Journal, 2018, 8, 18.	2.8	19
129	Screening for <scp>ASXL</scp>1 and <scp>SRSF</scp>2 mutations is imperative for treatment decisionâ€making in otherwise low or intermediateâ€1 risk patients with myelofibrosis. British Journal of Haematology, 2018, 183, 678-681.	1.2	19
130	Results from a Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate, or High Risk, Relapsed/Refractory Myelofibrosis. Blood, 2019, 134, 558-558.	0.6	19
131	Long-Term Follow Up Of a Randomized Phase II Study Of The JAK2-Selective Inhibitor Fedratinib (SAR302503) In Patients With Myelofibrosis (MF). Blood, 2013, 122, 4047-4047.	0.6	19
132	BMS-911543, A Selective JAK2 Inhibitor: A Multicenter Phase 1/2a Study In Myelofibrosis. Blood, 2013, 122, 664-664.	0.6	19
133	Mayo CALR mutation type classification guide using alpha helix propensity. American Journal of Hematology, 2018, 93, E128-E129.	2.0	18
134	Deciphering the individual contribution of absolute neutrophil and monocyte counts to thrombosis risk in polycythemia vera and essential thrombocythemia. American Journal of Hematology, 2022, 97, E35.	2.0	18
135	Proposal for a revised classification of systemic mastocytosis. Blood, 2010, 115, 2720-2721.	0.6	17
136	Morphologically Occult Systemic Mastocytosis in Bone Marrow. American Journal of Clinical Pathology, 2015, 144, 493-502.	0.4	17
137	MPL-mutated essential thrombocythemia: a morphologic reappraisal. Blood Cancer Journal, 2018, 8, 121.	2.8	17
138	Clinical outcomes of adults with hemophagocytic lymphohistiocytosis treated with the HLH-04 protocol: a retrospective analysis. Leukemia and Lymphoma, 2020, 61, 1592-1600.	0.6	17
139	Marked Elevation of Serum Lactate Dehydrogenase (LDH) in Primary Myelofibrosis: Clinical and Prognostic Correlates. Blood, 2016, 128, 3113-3113.	0.6	17
140	Primary Myelodysplastic Syndromes. Mayo Clinic Proceedings, 2015, 90, 1623-1638.	1.4	16
141	Mutations and karyotype in myelodysplastic syndromes: TP53 clusters with monosomal karyotype, RUNX1 with trisomy 21, and SF3B1 with inv(3)(q21q26.2) and del(11q). Blood Cancer Journal, 2017, 7, 658.	2.8	16
142	Smoldering mastocytosis: Survival comparisons with indolent and aggressive mastocytosis. American Journal of Hematology, 2019, 94, E1-E2.	2.0	16
143	An Expanded Multicenter Phase I/II Study of CYT387, a JAK- 1/2 Inhibitor for the Treatment of Myelofibrosis,. Blood, 2011, 118, 3849-3849.	0.6	16
144	U2AF1 mutation variants in myelodysplastic syndromes and their clinical correlates. American Journal of Hematology, 2018, 93, E146-E148.	2.0	15

#	Article	IF	Citations
145	Treatmentâ€refractory idiopathic hypereosinophilic syndrome: Pitfalls and progress with use of novel drugs. American Journal of Hematology, 2012, 87, 703-706.	2.0	14
146	Pregnancy outcomes in myeloproliferative neoplasms: A Mayo Clinic report on 102 pregnancies. American Journal of Hematology, 2020, 95, E114-E117.	2.0	14
147	Targeted Next-Generation Sequencing in Polycythemia Vera and Essential Thrombocythemia. Blood, 2015, 126, 354-354.	0.6	14
148	Cladribine therapy for advanced and indolent systemic mastocytosis: Mayo Clinic experience in 42 consecutive cases. British Journal of Haematology, 2022, 196, 975-983.	1.2	14
149	Pruritus in primary myelofibrosis: management options in the era of JAK inhibitors. Annals of Hematology, 2016, 95, 1185-1189.	0.8	13
150	Marked elevation of serum lactate dehydrogenase in primary myelofibrosis: clinical and prognostic correlates. Blood Cancer Journal, 2017, 7, 657.	2.8	13
151	Phase I/II Study of CYT387, a JAK1/JAK2 Inhibitor for the Treatment of Myelofibrosis. Blood, 2012, 120, 178-178.	0.6	13
152	Concurrent activating <scp>KIT</scp> mutations in systemic mastocytosis. British Journal of Haematology, 2016, 173, 153-156.	1.2	12
153	The prognostic relevance of serum lactate dehydrogenase and mild bone marrow reticulin fibrosis in essential thrombocythemia. American Journal of Hematology, 2017, 92, 454-459.	2.0	12
154	A Test Utilization Approach to the Diagnostic Workup of Isolated Eosinophilia in Otherwise Morphologically Unremarkable Bone Marrow. American Journal of Clinical Pathology, 2018, 150, 421-431.	0.4	12
155	World Health Organization class-independent risk categorization in mastocytosis. Blood Cancer Journal, 2019, 9, 29.	2.8	12
156	Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Relapsed/Refractory Chronic Myelomonocytic Leukemia (CMML). Blood, 2018, 132, 1821-1821.	0.6	12
157	Characterization of JAK2 V617F Allele Burden in Advanced Myelofibrosis (MF) Patients: No Change in V617F:WT JAK2 Ratio in Patients with High Allele Burdens despite Profound Clinical Improvement Following Treatment with the JAK Inhibitor, INCB018424. Blood, 2008, 112, 2802-2802.	0.6	12
158	The Clinical Phenotype of Myelofibrosis Encompasses a Chronic Inflammatory State That Is Favorably Altered by INCB018424, a Selective Inhibitor of JAK1/2. Blood, 2008, 112, 2804-2804.	0.6	12
159	SAR302503: Interim Safety, Efficacy and Long-Term Impact on JAK2 V617F Allele Burden in a Phase I/II Study in Patients with Myelofibrosis,. Blood, 2011, 118, 3838-3838.	0.6	12
160	JAK2 wild-type erythrocytosis associated with sodium-glucose cotransporter 2 inhibitor therapy. Blood, 2021, 138, 2886-2889.	0.6	12
161	The germline JAK2 GGCC (46/1) haplotype and survival among 414 molecularlyâ€annotated patients with primary myelofibrosis. American Journal of Hematology, 2019, 94, 299-305.	2.0	11
162	Young platelet millionaires with essential thrombocythemia. American Journal of Hematology, 2021, 96, E93-E95.	2.0	11

#	Article	IF	Citations
163	Extreme thrombocytosis in lowâ€risk essential thrombocythemia: Retrospective review of vascular events and treatment strategies. American Journal of Hematology, 2021, 96, E182-E184.	2.0	11
164	Imetelstat, a Telomerase Inhibitor, Induces Morphologic and Molecular Remissions In Myelofibrosis and Reversal Of Bone Marrow Fibrosis. Blood, 2013, 122, 662-662.	0.6	11
165	Midostaurin therapy for advanced systemic mastocytosis: Mayo Clinic experience in 33 consecutive cases. American Journal of Hematology, 2022, 97, 630-637.	2.0	11
166	20+ Years and alive with primary myelofibrosis: Phenotypic signature of very longâ€lived patients. American Journal of Hematology, 2019, 94, 286-290.	2.0	10
167	A Multicenter Phase 1/2 Clinical Trial of Tagraxofusp, a CD123-Targeted Therapy, in Patients with Poor-Risk Primary and Secondary Myelofibrosis. Blood, 2020, 136, 39-40.	0.6	10
168	A Phase II Randomized Dose-Ranging Study of the JAK2-Selective Inhibitor SAR302503 in Patients with Intermediate-2 or High-Risk Primary Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, or Post-Essential Thrombocythemia (ET) MF.. Blood, 2012, 120, 2837-2837.	0.6	10
169	Realâ€world experience with venetoclax and hypomethylating agents in myelodysplastic syndromes with excess blasts. American Journal of Hematology, 2022, 97, .	2.0	10
170	Germline SH2B3 pathogenic variant associated with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. American Journal of Hematology, 2019, 94, E231-E234.	2.0	9
171	A prospective evaluation of vitamin B1 (thiamine) level in myeloproliferative neoplasms: clinical correlations and impact of JAK2 inhibitor therapy. Blood Cancer Journal, 2019, 9, 11.	2.8	9
172	Prevalence and spectrum of T-cell lymphoproliferative disorders in patients with Hypereosinophilia: A reference laboratory experience. Annals of Diagnostic Pathology, 2020, 44, 151412.	0.6	9
173	De novo isolated myeloid sarcoma: comparative analysis of survival in 19 consecutive cases. British Journal of Haematology, 2021, 195, 413-416.	1.2	9
174	IPSS-Independent Cytogenetic Risk Categorization in Primary Myelofibrosis.. Blood, 2009, 114, 2909-2909.	0.6	9
175	Results from Ongoing Phase 2 Trial of SL-401 in Patients with Advanced, High-Risk Myeloproliferative Neoplasms Including Chronic Myelomonocytic Leukemia. Blood, 2016, 128, 4245-4245.	0.6	9
176	A populationâ€based study of outcomes in polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the United States from 2001 to 2015: Comparison with data from a Mayo Clinic single institutional series. American Journal of Hematology, 2021, 96, E464-E468.	2.0	9
177	The Effect of Number of Metaphases Studied and Abnormal Metaphase Percentage On Cytogenetic Risk Stratification in Primary Myelofibrosis. Blood, 2012, 120, 1742-1742.	0.6	9
178	Survival Trends in Essential Thrombocythemia in the Face of Changing Treatment Practices. Blood, 2015, 126, 2805-2805.	0.6	9
179	Cytogenetic abnormalities in essential thrombocythemia: Clinical and molecular correlates and prognostic relevance in 809 informative cases. Blood Cancer Journal, 2022, 12, 44.	2.8	9
180	Primary eosinophilic disorders: A concise review. Current Hematologic Malignancy Reports, 2008, 3, 37-43.	1.2	8

#	Article	IF	Citations
181	Early thrombotic events and preemptive systemic anticoagulation following splenectomy for myelofibrosis. American Journal of Hematology, 2018, 93, E235-E238.	2.0	8
182	A population-based study of chronic neutrophilic leukemia in the United States. Blood Cancer Journal, 2020, 10, 68.	2.8	8
183	The Impact of Obesity on the Outcomes of Adult Patients with Acute Lymphoblastic Leukemia â€“ A Single Center Retrospective Study. Blood and Lymphatic Cancer: Targets and Therapy, 2021, Volume 11, 1-9.	1.2	8
184	Highâ€oxygenâ€affinity hemoglobinopathyâ€associated erythrocytosis: Clinical outcomes and impact of therapy in 41 cases. American Journal of Hematology, 2021, 96, 1647-1654.	2.0	8
185	Serum erythropoietin levels in essential thrombocythemia: phenotypic and prognostic correlates. Blood Cancer Journal, 2018, 8, 118.	2.8	7
186	Decreased survival and increased rate of fibrotic progression in essential thrombocythemia chronicled after the FDA approval date of anagrelide. American Journal of Hematology, 2019, 94, 5-9.	2.0	7
187	Acute myeloid leukemia after age 70â€‰years: A retrospective comparison of survival following treatment with intensive versus <scp>HMA</scp>â€‰Â±â€‰venetoclax chemotherapy. American Journal of Hematology, 2021, 96, E108-E111.	2.0	7
188	Clinical and biological characteristics and prognostic impact of somatic GATA2 mutations in myeloid malignancies: a single institution experience. Blood Cancer Journal, 2021, 11, 122.	2.8	7
189	Concomitant Analysis of EZH2 and ASXL1 Mutations In Myelofibrosis, Chronic Myelomonocytic Leukemia and Blast-Phase Myeloproliferative Neoplasms. Blood, 2010, 116, 3070-3070.	0.6	7
190	Survival and Prognosis Among 1,263 Patients with Polycythemia Vera: An International Study. Blood, 2011, 118, 277-277.	0.6	7
191	Midostaurin therapy for indolent and smoldering systemic mastocytosis: Retrospective review of Mayo Clinic experience. American Journal of Hematology, 2022, 97, .	2.0	7
192	Limited activity of fedratinib in myelofibrosis patients relapsed/refractory to ruxolitinib 20â€‰mg twice daily or higher: A realâ€world experience. British Journal of Haematology, 2022, 198, .	1.2	7
193	A dynamic 3â€factor survival model for acute myeloid leukemia that accounts for response to induction chemotherapy. American Journal of Hematology, 2022, 97, 1127-1134.	2.0	7
194	Etiologies of Extreme Thrombocytosis: A Contemporary Series. Mayo Clinic Proceedings, 2019, 94, 1542-1550.	1.4	6
195	A populationâ€based study of chronic eosinophilic <scp>leukemiaâ€not</scp> otherwise specified in the United States. American Journal of Hematology, 2020, 95, E257.	2.0	6
196	Mayo Clinic experience with 1123 adults with acute myeloid leukemia. Blood Cancer Journal, 2021, 11, 46.	2.8	6
197	Risk Factors for Arterial Versus Venous Thrombosis in Polycythemia Vera: Single Center Experience in 587 Patients. Blood, 2016, 128, 948-948.	0.6	6
198	MPLW515L/K and JAK2V617F Mutations: Single Colony Studies, Lineage Restriction, and Chronology of Clonal Emergence.. Blood, 2006, 108, 116-116.	0.6	6

#	Article	IF	Citations
199	Lymphocytopenia predicts shortened survival in myelodysplastic syndrome with ring sideroblasts (<scp>MDSâ€RS</scp>) but not in <scp>MDS</scp>/<scp>MPNâ€RSâ€T</scp>. American Journal of Hematology, 2022, 97, .	2.0	6
200	Is there a role for JAK inhibitors inBCR-ABL1-negative myeloproliferative neoplasms other than myelofibrosis?. Leukemia and Lymphoma, 2014, 55, 2706-2711.	0.6	5
201	Acquired factor V deficiency in myeloproliferative neoplasms: a Mayo Clinic series of 33 patients. British Journal of Haematology, 2015, 171, 875-879.	1.2	5
202	CSF3R T618I mutant chronic myelomonocytic leukemia (CMML) defines a proliferative CMML subtype enriched in ASXL1 mutations with adverse outcomes. Blood Cancer Journal, 2021, 11, 54.	2.8	5
203	Mutation-Enhanced International Prognostic Systems for Essential Thrombocythemia (MIPSS-ET) and Polycythemia Vera (MIPSS-PV). Blood, 2018, 132, 578-578.	0.6	5
204	TG101209, a Selective JAK2 Kinase Inhibitor, Suppresses Endogenous and Cytokine-Supported Colony Formation from Hematopoietic Progenitors Carrying JAK2V617F or MPLW515K/L Mutations.. Blood, 2006, 108, 2680-2680.	0.6	5
205	Decreased Levels of Total or HDL Cholesterol in Primary Myelofibrosis Are Associated with Shortened Survival: DIPSS-Plus Independent Prognostic Value.. Blood, 2012, 120, 2851-2851.	0.6	5
206	Aurora A Kinase Is a Novel Therapeutic Target In The Myeloproliferative Neoplasms. Blood, 2013, 122, 109-109.	0.6	5
207	IDH mutations in Primary Myelofibrosis Predict Leukemic Transformation and Shortened Survival: Clinical Evidence for Leukemogenic Collaboration with JAK2V617F. Blood, 2011, 118, 1751-1751.	0.6	5
208	Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients. Blood Cancer Journal, 2022, 12, 26.	2.8	5
209	Mast cell sarcoma: 2 Mayo Clinic cases. American Journal of Hematology, 2022, 97, 1381-1383.	2.0	5
210	Systemic mastocytosis: evolving lessons from large patient registry datasets. American Journal of Hematology, 2016, 91, 654-655.	2.0	4
211	Phenotypic heterogeneity associated with germline GATA2 haploinsufficiency: a comprehensive kindred study. Leukemia and Lymphoma, 2019, 60, 3282-3286.	0.6	4
212	Determinants of long-term outcome in type 1 calreticulin-mutated myelofibrosis. Leukemia, 2019, 33, 780-785.	3.3	4
213	Clinical utility of fluorescence in situ hybridizationâ€based diagnosis of BCRâ€ABL1 like (<scp>P</scp>hiladelphia chromosome like) <scp>B</scp>â€acute lymphoblastic leukemia. American Journal of Hematology, 2020, 95, E68-E72.	2.0	4
214	Erythrocytosis associated with cerebral hemangiomas and multiple venous anomalies. American Journal of Hematology, 2020, 95, 1224-1225.	2.0	4
215	LNK Mutation Studies In Chronic- and Blast-Phase Myeloproliferative Neoplasms and JAK2 Mutation-Negative Erythrocytosis. Blood, 2010, 116, 4105-4105.	0.6	4
216	Longer-Term Follow up with TG101348 Therapy In Myelofibrosis Confirms Sustained Improvement In Splenomegaly, Disease-Related Symptoms, and JAK2V617F Allele Burden. Blood, 2010, 116, 459-459.	0.6	4

#	Article	IF	Citations
217	Comprehensive Cytokine Profiling in Systemic Mastocytosis: Prognostic Relevance of Increased Plasma IL-2R Levels.. Blood, 2012, 120, 2836-2836.	0.6	4
218	Momelotinib Therapy in Myelofibrosis: 6-Years Follow-up Data on Safety, Efficacy and the Impact of Mutations on Overall and Relapse-Free Survival. Blood, 2016, 128, 1123-1123.	0.6	4
219	The Germline JAK2 GGCC (46/1) Haplotype and Survival Among 414 Molecularly-Annotated Patients with Primary Myelofibrosis. Blood, 2018, 132, 1761-1761.	0.6	4
220	Functional Interrogation of Variants of Undetermined Significance of the Isocitrate Dehydrogenase 1 and 2 Genes in Myeloid Neoplasms. Blood, 2019, 134, 1697-1697.	0.6	4
221	Erythrocytosis associated with <i>EPAS1</i>(<i>HIF2A</i>), <i>EGLN1</i>(<i>PHD2</i>), <i>VHL, EPOR</i> or <i>BPGM</i> mutations: The Mayo Clinic experience. Haematologica, 2022, 107, 1201-1204.	1.7	4
222	Drugâ€“drug interaction between bosutinib and warfarin. Leukemia and Lymphoma, 2014, 55, 2213-2214.	0.6	3
223	Current treatment preferences in chronic myeloid leukemia: The Mayo Clinic Physicians' survey. American Journal of Hematology, 2017, 92, E626-E627.	2.0	3
224	A novel predictive model of outcome in acute myeloid leukemia without favorable karyotype based on treatment strategy, karyotype and FLT3â€ITD mutational status. American Journal of Hematology, 2018, 93, E401-E404.	2.0	3
225	Phenotypic correlates and prognostic outcomes of <scp>TET2</scp> mutations in myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: A comprehensive study of 504 adult patients. American Journal of Hematology, 2020, 95, E86-E89.	2.0	3
226	Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate or High Risk Relapsed/Refractory Myelofibrosis. Blood, 2018, 132, 1773-1773.	0.6	3
227	Circulating IL-2R, IL-8, IL-15 and CXCL10 Levels Are Independently Prognostic In Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study. Blood, 2010, 116, 3068-3068.	0.6	3
228	Characterization of BMS-911543, a Functionally Selective Small Molecule Inhibitor of JAK2. Blood, 2010, 116, 4112-4112.	0.6	3
229	Aberrant Megakaryocyte Gene Expression Contributes to Primary Myelofibrosis.. Blood, 2012, 120, 2867-2867.	0.6	3
230	Effect of the Number of Prognostically Relevant Mutated Genes on Survival and Leukemia Progression in Primary Myelofibrosis. Blood, 2013, 122, 104-104.	0.6	3
231	Myeloid Sarcoma: The Mayo Clinic Experience of Ninety Six Case Series. Blood, 2016, 128, 2798-2798.	0.6	3
232	Monocytosis Is a Powerful and Independent Predictor of Shortened Overall and Leukemia-Free Survival in Primary Myelofibrosis. Blood, 2016, 128, 4249-4249.	0.6	3
233	Normal Karyotype Primary Myelofibrosis (NK-PMF): Clinical and Molecular Prognostication In 690 Patients. Blood, 2013, 122, 1587-1587.	0.6	3
234	<i>SF3B1</i>-mutant myelodysplastic syndrome/myeloproliferative neoplasms: a unique molecular and prognostic entity. Haematologica, 2022, 107, 1189-1192.	1.7	3

#	Article	IF	Citations
235	Preâ€anthracycline echocardiogram rarely changes treatment strategy in acute myeloid leukemia. American Journal of Hematology, 2018, 93, E144-E146.	2.0	2
236	Practiceâ€relevant demarcation of systemic mastocytosis associated with another hematologic neoplasm. American Journal of Hematology, 2018, 93, E383-E386.	2.0	2
237	Pregnancy in patients with myelofibrosis: Mayoâ€“Florence series of 24 pregnancies in 16 women. British Journal of Haematology, 2021, 195, 133-137.	1.2	2
238	Choosing the Right Patients for Clinical Trials in Essential Thrombocythemia or Polycythemia Vera: Leukemic or Fibrotic Transformation Risk Assessment among 1061 Patients from a Single Institution.. Blood, 2007, 110, 3546-3546.	0.6	2
239	Epigenomic Profiling of Myeloproliferative Diseases Reveal Idiopathic Myelofibrosis as An Epigenetically Distinct Subgroup and Highlights the Epigenetic Effects of Jak2V617F Mutation. Blood, 2010, 116, 627-627.	0.6	2
240	SF3B1 Mutations Are Prevalent in Myelodysplastic Syndromes with Ring Sideroblasts but Do Not Hold Independent Prognostic Value. Blood, 2011, 118, 460-460.	0.6	2
241	Spectrum of Mutations Associated with Hereditary Erythrocytosis. Blood, 2015, 126, 2140-2140.	0.6	2
242	ASXL1 and CBL Mutations Are Independently Predictive of Inferior Survival in Advanced Systemic Mastocytosis. Blood, 2015, 126, 828-828.	0.6	2
243	Prefibrotic Versus Overtly Fibrotic Primary Myelofibrosis: Clinical, Cytogenetic, Molecular and Prognostic Comparisons. Blood, 2016, 128, 4247-4247.	0.6	2
244	Low JAK2V617F Allele Burden in Primary Myelofibrosis, Compared to Either a Higher Allele Burden or Unmutated Status, Predicts Inferior Overall and Leukemia-Free Survival.. Blood, 2007, 110, 676-676.	0.6	2
245	Long-Term Outcome of Treatment with Ruxolitinib in Myelofibrosis. Blood, 2011, 118, 1752-1752.	0.6	2
246	ASXL1 Mutations in Myelodysplastic Syndromes with 1% or More Ring Sideroblasts: Prevalence, Clinical Correlates and Prognostic Relevance. Blood, 2015, 126, 2882-2882.	0.6	2
247	Safety and Tolerability of Lurbinectedin (PM01183) in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. Blood, 2018, 132, 2722-2722.	0.6	2
248	A Globally Applicable "Triple AAA" Risk Model for Essential Thrombocythemia Based on Age, Absolute Neutrophil Count, and Absolute Lymphocyte Count. Blood, 2021, 138, 238-238.	0.6	2
249	A role for tryptase in myeloid disorders?. Leukemia and Lymphoma, 2006, 47, 789-790.	0.6	1
250	Dysregulated EVI1 expression in myeloid malignancies. Leukemia and Lymphoma, 2006, 47, 2443-2444.	0.6	1
251	The impact of sex on disease phenotype and prognostic thresholds of anemia in myelodysplastic syndromes. American Journal of Hematology, 2018, 93, E164-E167.	2.0	1
252	Normal karyotype in myelofibrosis: is prognostic integrity affected by the number of metaphases analyzed?. Blood Cancer Journal, 2018, 8, 8.	2.8	1

#	Article	IF	Citations
253	A retrospective survey of exposure history to chemotherapy or radiotherapy in 940 consecutive patients with primary myelofibrosis. American Journal of Hematology, 2018, 93, E103-E107.	2.0	1
254	Genetic predictors of response to specific drugs in primary myelofibrosis. Blood Cancer Journal, 2018, 8, 120.	2.8	1
255	Cytogenetic clonal evolution in myeloproliferative neoplasms: contexts and prognostic impact among 648 patients with serial bone marrow biopsies. Leukemia, 2019, 33, 2522-2553.	3.3	1
256	Mutations and prognosis in myeloproliferative neoplasms. Leukemia and Lymphoma, 2019, 60, 1112-1113.	0.6	1
257	20+ Years and Alive with Primary Myelofibrosis: Phenotypic Signature of Very Long-Lived Patients. Blood, 2018, 132, 4301-4301.	0.6	1
258	3,023 Mayo Clinic Patients with Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. Blood, 2018, 132, 3035-3035.	0.6	1
259	Mutations and Thrombosis in Essential Thrombocythemia and Polycythemia Vera: Mayo-Careggi Alliance Study. Blood, 2018, 132, 3040-3040.	0.6	1
260	Spectrum of Abnormalities and Clonal Transformation in Germline RUNX1 Familial Platelet Disorder and a Comparative Analysis with Somatic RUNX1 Mutations in Myeloid Neoplasms. Blood, 2019, 134, 3003-3003.	0.6	1
261	TG101348, An Orally Bioavailable JAK2-Selective Inhibitor, Potently Inhibits KITD816V and FIP1L1-PDGFRA in Vitro. Blood, 2008, 112, 2807-2807.	0.6	1
262	Pomalidomide Therapy for Myelofibrosis: Analysis of Results From Three Consecutive Clinical Trials. Blood, 2011, 118, 1759-1759.	0.6	1
263	Comprehensive Plasma Cytokine Profiling in Polycythemia Vera: Comparison with Myelofibrosis and Clinical Correlates,. Blood, 2011, 118, 3850-3850.	0.6	1
264	Clonal Evolution As Determined By Sequential Bone Marrow Karyotype Analysis During JAK Inhibitor Therapy For Myelofibrosis: Impact On Treatment Response and Overall and Leukemia-Free Survival. Blood, 2013, 122, 2821-2821.	0.6	1
265	Chronic Neutrophilic Leukemia With Concurrent CSF3R and SETBP1 Mutations: Single Colony Clonality Studies, In Vitro Sensitivity To JAK Inhibitors and Lack Of Treatment Response To Ruxolitinib. Blood, 2013, 122, 2830-2830.	0.6	1
266	Retrospective Comparison Of Survival and Leukemic Transformation In Myelofibrosis Patients Treated With Ruxolitinib Versus Momelotinib Versus Fedratinib Versus Pomalidomide. Blood, 2013, 122, 4049-4049.	0.6	1
267	Driver Mutations and Prognosis in 502 Patients with Essential Thrombocythemia. Blood, 2015, 126, 1599-1599.	0.6	1
268	Driver Mutations and Prognosis in 1118 Patients with Primary Myelofibrosis. Blood, 2015, 126, 2801-2801.	0.6	1
269	Peripheral Blood JAK2V617F Quantitative Assessment in Clinical Practice: Correlations Between Allele Burden and Clinical Phenotype. Blood, 2015, 126, 2819-2819.	0.6	1
270	A 27-Gene NGS Panel in Primary Myelofibrosis Identifies ASXL1, CBL, RUNX1 and SRSF2 Mutations As Being Unfavorable and Absence of Any Non-Driver Mutation As Being Favorable to Survival. Blood, 2015, 126, 350-350.	0.6	1

#	Article	IF	Citations
271	Busulfan for the Treatment of Myeloproliferative Neoplasms: The Mayo Clinic Experience. Blood, 2015, 126, 4078-4078.	0.6	1
272	Abnormal Karyotype and Prognosis in Polycythemia Vera: A Single Center Experience in 239 Informative Cases. Blood, 2016, 128, 3115-3115.	0.6	1
273	U2AF1 Mutation Variants and Their Phenotypic and Prognostic Relevance in Primary Myelofibrosis. Blood, 2016, 128, 4248-4248.	0.6	1
274	Low Incidence of FIP1L1-PDGFRA in Eosinophilic Patients and Long-Term Experience with Imatinib Therapy.. Blood, 2005, 106, 2590-2590.	0.6	1
275	DIPSS-Plus: A Refined Dynamic International Prognostic Scoring System (DIPSS) for Primary Myelofibrosis That Incorporates Karyotype, Platelet Count and Transfusion Status. Blood, 2010, 116, 4104-4104.	0.6	1
276	A Phase-2 Trial of Low-Dose Pomalidomide In Myelofibrosis with Anemia. Blood, 2010, 116, 4109-4109.	0.6	1
277	Immunoglobulin Free Light Chain Levels Predict Survival in Primary Myelofibrosis and De Novo Myelodysplastic Syndromes. Blood, 2011, 118, 1756-1756.	0.6	1
278	Initial presentation of CNS-restricted acute lymphoblastic B cell leukaemia as peripheral polyneuropathy. BMJ Case Reports, 2016, 2016, bcr2016214645.	0.2	1
279	Subnormal Lymphocyte Count Predicts Inferior Survival in Myelodysplastic Syndromes: A Single Center Experience in 889 Patients. Blood, 2016, 128, 5534-5534.	0.6	1
280	Identification of Serum Lactate Dehydrogenase (LDH) As an Independent Prognostic Biomarker in Polycythemia Vera. Blood, 2016, 128, 3111-3111.	0.6	1
281	The Clinical Utility of Pharmacogenomics Testing in Assessing Tyrosine Kinase Inhibitor Therapy, Intolerance and Responses in Patients with Chronic Myelogenous Leukemia. Blood, 2018, 132, 5440-5440.	0.6	1
282	Response to Erythropoiesis Stimulating Agents in Patients with WHO-Defined Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T). Blood, 2019, 134, 4182-4182.	0.6	1
283	Acute Myeloid Leukemia with High Risk Features: Routine Central Nervous System Evaluation May be Beneficial. Blood, 2019, 134, 3863-3863.	0.6	1
284	Deciphering the Individual Contribution of Absolute Neutrophil, Lymphocyte and Monocyte Counts to Thrombosis Risk in Patients with Myeloproliferative Neoplasms. Blood, 2021, 138, 3651-3651.	0.6	1
285	Cladribine Therapy for Advanced and Indolent Systemic Mastocytosis: Mayo Clinic Experience in 42 Consecutive Cases. Blood, 2021, 138, 3657-3657.	0.6	1
286	Acute Myeloid Leukemia in the Context of Previous History of Cancer with or without Exposure to Chemotherapy or Radiotherapy. Blood, 2021, 138, 3368-3368.	0.6	1
287	Response criteria in systemic mastocytosis: moving forward with practical assessment that reflects meaningful health outcome. European Journal of Haematology, 2010, 85, no-no.	1.1	0
288	Functional evaluation of isocitrate dehydrogenase 1 and 2 variants of unclear significance in chronic myeloid neoplasms. Leukemia Research, 2019, 87, 106264.	0.4	0

#	Article	IF	Citations
289	Calculatorâ€free pointâ€ofâ€care prognostication in myelodysplastic syndromes. American Journal of Hematology, 2019, 94, E99-E101.	2.0	0
290	81-Year-Old Man With Insomnia and Pruritus. Mayo Clinic Proceedings, 2020, 95, e59-e64.	1.4	0
291	Single Nucleotide Polymorphism (SNP) Analysis of JAK2 and Relevant Cytokine Receptor Genes in Myeloproliferative Disorders.. Blood, 2006, 108, 661-661.	0.6	0
292	â€™Idiopathicâ€™ Eosinophilia with an Occult T-Cell Clone: Prevalence, FIP1L1-PDGFRA Status, and Clinical Course.. Blood, 2006, 108, 2701-2701.	0.6	0
293	Erythropoietin Therapy Does Not Benefit Transfusion-Dependent Primary Myelofibrosis Patients and Treatment Response Is Infrequent with a Baseline Hemoglobin Level â‰¥ 10 g/dL.. Blood, 2007, 110, 3555-3555.	0.6	0
294	Pruritus in Polycythemia Vera Is More Prevalent in Non-Smokers and Is Independently Associated with a Lower Risk of Arterial Thrombosis.. Blood, 2007, 110, 2550-2550.	0.6	0
295	JAK2V617F Mutation Screening as Part of the Hypercoagulable Workup in the Absence of Splanchnic Vein Thrombosis: Assessment of Value in a Series of 664 Consecutive Patients.. Blood, 2007, 110, 3191-3191.	0.6	0
296	Prognostically Relevant Breakdown of 138 Patients with Systemic Mastocytosis Associated with Another Hematological Malignancy. Blood, 2008, 112, 2808-2808.	0.6	0
297	Pathogenesis, Diagnosis, Classification, and Management of Systemic Mastocytosis. , 2011, , 205-221.		0
298	Refined Cytogenetic Risk Categorization for Overall and Leukemia-Free Survival In Primary Myelofibrosis: A Single Center Study of 433 Patients. Blood, 2010, 116, 4122-4122.	0.6	0
299	Monosomal Karyotype In Primary Myelofibrosis Is Prognostically Worse Than Otherwise Unfavorable Karyotype. Blood, 2010, 116, 3069-3069.	0.6	0
300	Long Term Follow-up and IWG-MRT Response Assessment for 50 Myelofibrosis (MF) Patients Treated with Thalidomide-Prednisone Based Regimens. Blood, 2010, 116, 4094-4094.	0.6	0
301	IDH Mutations and Trisomy 8 In Myelodysplastic Syndromes and Acute Myeloid Leukemia. Blood, 2010, 116, 4009-4009.	0.6	0
302	Predictors of Greater Than 80% Two-Year Mortality in Primary Myelofibrosis: A Mayo Clinic Study of 884 Karyotypically-Annotated Cases. Blood, 2011, 118, 2806-2806.	0.6	0
303	IPSS Independent Prognostic Value of Plasma CXCL10, IL-7 and IL-6 Levels in De Novo Myelodysplastic Syndromes,. Blood, 2011, 118, 3795-3795.	0.6	0
304	Prognostic Irrelevance of Vitamin D Insufficiency in Myeloproliferative Neoplasms and De Novo Myelodysplastic Syndromes. Blood, 2011, 118, 5158-5158.	0.6	0
305	Leukemia Risk Models in Primary Myelofibrosis: An International Working Group Study,. Blood, 2011, 118, 3833-3833.	0.6	0
306	Differential Prognostic Effect of IDH1 Versus IDH2 Mutations in Myelodysplastic Syndromes: A Mayo Clinic Study of 277 Patients. Blood, 2011, 118, 971-971.	0.6	0

#	Article	IF	Citations
307	Pruritus in Primary Myelofibrosis: Clinical and Laboratory Correlates. Blood, 2011, 118, 5154-5154.	0.6	0
308	CCDC26 Polymorphisms Are Differentially Expressed in Myeloid Malignancies with Mutant IDH1 Compared to Their IDH2R140-Mutated or IDH-Unmutated Counterparts. Blood, 2011, 118, 2807-2807.	0.6	0
309	Gene Expression Profiling within the Context of JAK Inhibitor Therapy for Myelofibrosis: Correlation with Treatment Effect and Anemia Response. Blood, 2012, 120, 1751-1751.	0.6	0
310	Spliceosome Mutations Involving SRSF2, SF3B1 and U2AF35 in World Health Organization Defined Chronic Myelomonocytic Leukemia; Prevalence, Clinical Correlates and Prognosis. Blood, 2012, 120, 1711-1711.	0.6	0
311	Phenotypic and Prognostic Correlates of Spliceosome Mutations (SRSF2, SF3B1, U2AF35) in Chronic Myelomonocytic Leukemia with â‰¥ 1% Ring Sideroblasts.. Blood, 2012, 120, 2803-2803.	0.6	0
312	Survival and Prognosis in World Health Organization Defined Chronic Myelomonocytic Leukemia- A Mayo Clinic Series of 227 Patients. Blood, 2012, 120, 3790-3790.	0.6	0
313	Prognostic Interactions Between SRSF2, ASXL1, and IDH Mutations in Primary Myelofibrosis and Determination of Added Value to Cytogenetic Risk Stratification and DIPSS-Plus. Blood, 2012, 120, 430-430.	0.6	0
314	Evaluation of IPSS-Revised (IPSS-R) Cytogenetic Risk Stratification and Prognostic Impact of Monosomal Karyotype in 1,014 Patients with Myelodysplastic Syndromes (MDS). Blood, 2012, 120, 423-423.	0.6	0
315	Associations and Prognostic Interactions Between Circulating Levels of Hepcidin, Ferritin, and Inflammatory Cytokines in Primary Myelofibrosis.. Blood, 2012, 120, 2831-2831.	0.6	0
316	Risk Factors for Thrombosis Among 1,545 Patients with Polycythemia Vera: An International Study.. Blood, 2012, 120, 2849-2849.	0.6	0
317	Serum Ferritin Level At Referral Provides Independent Prognostic Information For Overall Survival In Primary Myelofibrosis. Blood, 2013, 122, 2824-2824.	0.6	0
318	U2AF1 mutations In Primary Myelofibrosis Cluster With Normal Karyotype and JAK2V617F and Are Strongly Associated With Anemia and Thrombocytopenia. Blood, 2013, 122, 4060-4060.	0.6	0
319	Baseline Spleen Size and Mutations Involving ASXL1 and SRSF2 Predict Survival and Treatment Response In JAK Inhibitor Treated Myelofibrosis Patients. Blood, 2013, 122, 4048-4048.	0.6	0
320	Cytogenetic Abnormalities Predict Clinical Outcome In Patients Diagnosed With Relapsed Acute Myeloid Leukemia (rAML): Single Center Experience. Blood, 2013, 122, 4955-4955.	0.6	0
321	Management Of PICC-Associated Thrombosis In Patients Receiving Chemotherapy For Hematologic Malignancies. Blood, 2013, 122, 5000-5000.	0.6	0
322	Arterial Versus Venous Events in Essential Thrombocythemia and Their Impact on Overall and Thrombosis Free Survival. Blood, 2015, 126, 1611-1611.	0.6	0
323	Momelotinib Therapy for Myelofibrosis: Impact on Long-Term Survival and Genotype Correlations. Blood, 2015, 126, 4062-4062.	0.6	0
324	Molecular Correlates of Anemia in Primary Myelofibrosis. Blood, 2015, 126, 4068-4068.	0.6	0

#	Article	IF	Citations
325	CD123 Immunostaining in Systemic Mastocytosis: Differential Expression in Disease Subgroups and Potential Prognostic Value. Blood, 2015, 126, 2802-2802.	0.6	0
326	Survival Trends in Primary Myelodysplastic Syndromes: A Comparative Analysis of 1000 Patients By Year of Diagnosis and Treatment. Blood, 2015, 126, 2875-2875.	0.6	0
327	Prognostic Impact of Bone Marrow Fibrosis in Polycythemia Vera: Validation of the IWG-MRT Study and Additional Observations. Blood, 2016, 128, 3129-3129.	0.6	0
328	Prognostic Relevance of Monocytopenia and Lymphocyte-to-Monocyte Ratio in Primary Myelodysplastic Syndromes. Blood, 2016, 128, 1996-1996.	0.6	0
329	Monocytosis in Polycythemia Vera: Clinical and Molecular Correlates. Blood, 2016, 128, 4259-4259.	0.6	0
330	Next-Generation Sequencing in Myelodysplastic Syndromes: Prognostic Interaction Between Adverse Mutations and IPSS-R. Blood, 2016, 128, 1986-1986.	0.6	0
331	The Prognostic Relevance of Serum Lactate Dehydrogenase and Mild Reticulin Fibrosis in Essential Thrombocythemia. Blood, 2016, 128, 3120-3120.	0.6	0
332	Predictors of Spleen and Anemia Response to Specific Drugs in Primary Myelofibrosis. Blood, 2018, 132, 4300-4300.	0.6	0
333	Serum Erythropoietin Levels in Essential Thrombocythemia: Phenotypic and Prognostic Correlates. Blood, 2018, 132, 3034-3034.	0.6	0
334	Decreased Survival and Increased Rate of Fibrotic Progression in Essential Thrombocythemia Chronicled after the FDA Approval Date of Anagrelide. Blood, 2018, 132, 4287-4287.	0.6	0
335	Clinical and Molecular Models of Prognostication in Mastocytosis: Analysis Based on 580 Consecutive Cases. Blood, 2018, 132, 582-582.	0.6	0
336	Determinants of Long-Term Outcome in Type 1/like Calreticulin-Mutated Myelofibrosis. Blood, 2018, 132, 1767-1767.	0.6	0
337	Indoleamine 2,3-Dioxygenase-1 Expressing Dendritic Cell Populations Are Associated with Tumor-Induced Immune Tolerance & Aggressive Disease Biology in Chronic Myelomonocytic Leukemia. Blood, 2018, 132, 4344-4344.	0.6	0
338	Cytogenetic Abnormalities in Systemic Mastocytosis: Who Subcategory-Specific Incidence and Prognostic Impact Among 348 Informative Cases. Blood, 2018, 132, 3050-3050.	0.6	0
339	Myeloproliferative Neoplasms in Young Patients: The Mayo Clinic Experience with 361 Cases Age 40 Years or Younger. Blood, 2018, 132, 3033-3033.	0.6	0
340	Cytogenetic Clonal Evolution in Myeloproliferative Neoplasms: Contexts and Prognostic Impact Among 650 Patients with Serial Bone Marrow Biopsies. Blood, 2018, 132, 4291-4291.	0.6	0
341	MPL-Mutated Essential Thrombocythemia: A Morphologic Reappraisal. Blood, 2018, 132, 3036-3036.	0.6	0
342	Clinical Correlates, Prognostic Impact and Survival Outcomes in Chronic Myelomonocytic Leukemia Patients with Myeloproliferative Neoplasm Associated-Driver Mutations. Blood, 2018, 132, 3100-3100.	0.6	0

#	Article	IF	Citations
343	1,123 Consecutive Adults with Non-APL Acute Myeloid Leukemia: The Mayo Clinic Experience. Blood, 2018, 132, 2689-2689.	0.6	0
344	Risk Factors for Leukemic Transformation Among 1,306 Patients with Primary Myelofibrosis: Mutations Predict Early Events. Blood, 2018, 132, 3044-3044.	0.6	0
345	A Prospective Evaluation of Vitamin B1 (thiamine) Level in Myeloproliferative Neoplasms: Clinical Correlations and Impact of JAK2 Inhibitor Therapy. Blood, 2018, 132, 1771-1771.	0.6	0
346	Phenotypic Correlates and Prognostic Outcomes of TET2 Mutations in Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes: A Comprehensive Study of 504 Patients. Blood, 2019, 134, 3005-3005.	0.6	0
347	Clinical Categorization of Chronic Myelomonocytic Leukemia into Proliferative and Dysplastic Subtypes Correlates with Distinct Genomic, Transcriptomic and Epigenomic Signatures. Blood, 2019, 134, 1710-1710.	0.6	0
348	High-Oxygen-Affinity Hemoglobinopathy-Associated Erythrocytosis: Clinical Outcomes and Impact of Therapy in 41 Cases. Blood, 2021, 138, 1492-1492.	0.6	0
349	Anthracycline Choices for Induction Chemotherapy Among 797 Consecutive Adult Patients with Acute Myeloid Leukemia: Daunorubicin-60 Vs Idarubicin-12 Vs Daunorubicin-90. Blood, 2021, 138, 1267-1267.	0.6	0
350	The 1.5 Million Platelet Count Threshold in Essential Thrombocythemia: Phenotype and Genotype Correlates and Relevance to Vascular Events. Blood, 2021, 138, 3630-3630.	0.6	0
351	Spectrum of Hematological Malignancies in 130 Patients with Germline Predisposition Syndromes - Mayo Clinic Germline Predisposition Study. Blood, 2020, 136, 34-35.	0.6	0
352	Clinical, Molecular, and Prognostic Comparisons between Clonal Cytopenias of Undetermined Significance and Lower-Risk Myelodysplastic Syndromes - a Study of 184 Molecularly Annotated Patients. Blood, 2020, 136, 35-36.	0.6	0
353	A Population-Based Study of Chronic Myelomonocytic Leukemia in the United States from 2004-2015. Blood, 2020, 136, 30-31.	0.6	0
354	Pre- Transplant Ferritin Predicts Overall Survival and Non-Relapse Mortality in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis. Blood, 2020, 136, 19-20.	0.6	0